Carsgen presents research results on satri-cel in the lancet and at the 2025 asco annual meeting

Shanghai , june 1, 2025 /prnewswire/ -- carsgen therapeutics holdings limited (stock code: 2171.hk), a company focused on developing innovative car t-cell therapies, announces that the results of the pivotal phase ii clinical trial in china (ct041-st-01, nct04581473) investigating satricabtagene autoleucel ("satri-cel", ct041) (a claudin18.2-specific autologous car t-cell product candidate) in patients with claudin18.2-positive, advanced gastric/gastroesophageal junction cancer refractory to at least two prior lines of treatment, have been published in the lancet and were orally presented at the 2025 asco annual meeting. further details have been posted on the corporate website https://www.carsgen.com.
CAR Ratings Summary
CAR Quant Ranking